Phano e Lebeletsoeng ea Phano ea Lithethefatsi bakeng sa Lipetlele tsa Kankere

Phano ea Lithethefatsi e Lebeletsoeng bakeng sa Lipetlele tsa Mofets'e: Ho Ntlafatsa Phekolo ea Kalafo Lits'ebetso tse reriloeng tsa phano ea lithethefatsi li fetola kalafo ea mofetše, li fana ka ts'ebetso e ntlafetseng le litlamorao tse fokotsehileng ho bakuli. Sengoliloeng sena se hlalosa mekhoa e fapaneng e sebelisitsoeng phano ea lithethefatsi e lebisitsoeng ho lipetlele tsa mofetše, ho hlahloba mekhoa ea bona, melemo le mathata. Re tla hlahloba mehlala e ikhethileng mme re nahane ka bokamoso ba karolo ena ea bohlokoa ea oncology.

Ho utloisisa Phano ea Lithethefatsi e Lebeletsoeng

Phano ea Lithethefatsi e Lebeletsoeng ke Eng?

Ho fapana le chemotherapy ea setso, e tsamaisang lithethefatsi 'meleng, phano ea lithethefatsi e lebisitsoeng ho lipetlele tsa mofetše e tsepamisitse maikutlo ho faneng ka lisebelisoa tsa kalafo ka kotloloho liseleng tsa mofetše. Mokhoa ona o fokotsa tšenyo ea lisele tse phetseng hantle, tse lebisang litla-morao tse fokolang le liphello tse ntlafetseng tsa phekolo. Ho sebelisoa mekhoa e fapaneng ho fihlela phano ena e reriloeng, e 'ngoe le e 'ngoe e na le litšobotsi tse ikhethang le ts'ebeliso.

Mekhoa ea Phano ea Lithethefatsi e Lebeletsoeng

Mekhoa e mengata e thusa phano ea lithethefatsi e lebisitsoeng ho lipetlele tsa mofetše. Tsena li kenyelletsa:

• Li-antibody-drug conjugates (ADCs): Lithibela-mafu li tlama liseleng tsa mofetše ka ho khetheha, li jara moriana o khomaretsoeng ka kotloloho ho hlahala.
• Ho fana ka lithethefatsi tsa liposomal: Lithethefatsi li kenngoa ka har'a liposomes, tseo joale li lebisitsoeng ho lisele tsa mofetše li sebelisa li-ligands kapa li-antibodies tse itseng.
• Phano ea lithethefatsi ea Nanoparticle: Li-nanoparticles li ka etsoa ho isa lithethefatsi sebakeng sa hlahala, ka ho sebelisa phello e ntlafalitsoeng ea permeability le retention (EPR).
• Li-nanoparticles tse reriloeng: Tsena li sebelisa liphetoho tse holim'a metsi joalo ka li-ligands kapa li-antibodies bakeng sa ho shebana le lisele tsa tumor.

Mefuta ea Mekhoa e Lebeletsoeng ea Phano ea Lithethefatsi

Antibody-Drug Conjugates (ADCs)

Li-ADC ke mohlala o hlahelletseng oa phano ea lithethefatsi e lebisitsoeng ho lipetlele tsa mofetše. Li kopanya tse ikhethang tsa li-antibodies tsa monoclonal le matla a lithethefatsi tsa cytotoxic. Mokhoa ona o ntlafatsa katleho ka ho isa moriana ka kotloloho liseleng tsa mofetše, ha o ntse o boloka lisele tse phetseng hantle. Mohlala, trastuzumab emtansine (Kadcyla) ke ADC e sebelisetsoang ho phekola mofetše oa matsoele oa HER2-positive.¹

Phano ea Lithethefatsi tsa Liposomal

Liposomes li koahela moriana, ho o sireletsa ho senyeha le ho eketsa nako ea ho potoloha maling. Pharmacokinetics ena e ntlafalitsoeng e lumella ho tsamaisoa ho lebisitsoeng ho lisele tsa tumor ka li-ligands tse lebisitsoeng kapa ho bokella ho sa sebetseng ka phello ea EPR. Doxorubicin liposomes (mohlala, Doxil) ke mohlala o amohelehang oa tleliniki.²

Melemo le Mathata a Phano ea Lithethefatsi e Lebeletsoeng

Bokamoso ba Phano ea Lithethefatsi e Lebeletsoeng bakeng sa Lipetlele tsa Kankere

Lipatlisiso li tsoela pele ho ntlafatsa le ho atolosa menyetla ea phano ea lithethefatsi e lebisitsoeng ho lipetlele tsa mofetše. Tsoelo-pele ho nanotechnology, genomics, le litšoantšo li lebisa ho nts'etsopele ea mekhoa e tsoetseng pele le e sebetsang haholoanyane. Ho kopanngoa ha meriana ea motho ka mong le tšebeliso ea liphekolo tse kopaneng le tsona li bula tsela bakeng sa liphello tse ntlafetseng tsa phekolo ea mofetše. Bakeng sa tlhaiso-leseling e batsi mabapi le kalafo e tsoetseng pele ea mofets'e le lipatlisiso, etela Setsi sa Lipatlisiso sa Kankere sa Shandong Baofa.

¹ FDA. (n.d.). Kadcyla (trastuzumab emtansine). E ntšitsoe ho [https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm361642.htm](https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm361642.htm)

² FDA. (n.d.). DOXIL (ente ea doxorubicin HCl liposomal). E ntšitsoe ho [https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020515](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo51=0)